News

Integrative Corporate and Drug Development Engine

Strategic Alliance

Landmark BioVentures and G.CLIPS Biotech forge strategic alliance to address critical gaps in drug target engagement

04/23/25

Read more

Strategic Alliance

Landmark BioVentures strengthens immunology and oncology non-clinical capabilities through strategic alliance with Axis Bio

12/12/24

Read more

Company Launch

Duhn Therapeutics, launched by Landmark BioVentures, signs global license agreement with OM Pharma to further advance clinical-stage, lipid-based cancer immunotherapy

10/23/24

Read more

Company Launch

SPIMA Therapeutics Launches to Transform Peptide-Based Immunotherapies and Announces Global Licensing Agreement with SATT AxLR

09/30/24

Read more

Contact Us